StartsidaCMPS • NASDAQ
add
Compass Pathways PLC
3,67 $
Efter stängningsdags:(2,18 %)+0,080
3,75 $
Stängt: 3 mars, 16:04:27 GMT−5 · USD · NASDAQ · Ansvarsfriskrivning
Föregående stängning
3,93 $
Dygnsintervall
3,66 $ - 4,10 $
Årsintervall
3,17 $ - 12,57 $
Börsvärde
339,20 mn USD
Genomsnittlig volym
1,18 mn
Primär börs
NASDAQ
Aktuellt
Ekonomi
Resultaträkning
Intäkter
Nettoinkomst
| (USD) | dec. 2024info | Förändring Y/Y |
|---|---|---|
Intäkter | — | — |
Rörliga kostnader | 38,21 mn | 9,02 % |
Nettoinkomst | −43,33 mn | −33,20 % |
Nettovinstmarginal | — | — |
Vinst per aktie | −0,63 | −18,87 % |
EBITDA | −38,16 mn | −9,06 % |
Giltig skattesats | −2,42 % | — |
Balansräkning
Totala tillgångar
Totala ansvarsskyldigheter
| (USD) | dec. 2024info | Förändring Y/Y |
|---|---|---|
Kontanta och kortsiktiga investeringar | 165,08 mn | −25,03 % |
Totala tillgångar | 213,67 mn | −22,58 % |
Totala ansvarsskyldigheter | 58,97 mn | 17,37 % |
Totala tillgångar | 154,70 mn | — |
Utestående aktier | 92,67 mn | — |
P/B | 1,74 | — |
Avkastning på tillgångar | −41,44 % | — |
Avkastning på kapital | −46,32 % | — |
Kassaflöde
Förändring i nettokassa
| (USD) | dec. 2024info | Förändring Y/Y |
|---|---|---|
Nettoinkomst | −43,33 mn | −33,20 % |
Kontanter från verksamhet | −41,76 mn | −50,30 % |
Kontanter från investering | — | — |
Kontanter från finansiering | 155,00 tn | 278,05 % |
Förändring i nettokassa | −41,87 mn | −50,99 % |
Fritt kassaflöde | −44,04 mn | −133,07 % |
Om
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Grundades
13 juni 2016
Hemsida
Anställda
166
